tert-butyl (2S,4S)-4-methyl-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate | 1356956-76-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: tert-butyl (2S,4S)-4-methyl-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate
• 英文别名: tert-butyl (2S,4S)-4-methyl-2-[6-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate
• CAS: 1356956-76-7
• 化学式: C₂₉H₃₈BN₃O₄
• 分子量: 503.449
• InChiKey: DWUKSHSHYXKCCZ-UUOWRZLLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.85
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.52
• 拓扑面积：
  76.7
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl (2S,4S)-4-methyl-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate 在 palladium diacetate 、 碳酸氢钠 、 三氟乙酸 作用下， 以 二氯甲烷 、 水 、 异丙醇 为溶剂， 生成
  参考文献：
  名称：

  Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores

  摘要：

  Inhibitors of the HCV NS5A nonstructural protein are showing promising clinical potential in the treatment of hepatitis C when used in combination with other direct-acting antiviral agents. Current NS5A clinical candidates such as daclatasvir, ledipasvir, and ombitasvir share a common pharmacophore that features a pair of (S)-methoxycarbonylvaline capped pyrrolidines linked to various cores by amides, imidazoles and/or benzimidazoles. In this Letter, we describe the evaluation of NS5A inhibitors which contain alternative heteroaromatic replacements for these amide mimetics. The SAR knowledge gleaned in the optimization of scaffolds containing benzoxazoles was parlayed toward the identification of potent NS5A inhibitors containing other heteroaromatic replacements such as indoles and imidazopyridines. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.042
• 作为产物：
  描述：

  tert-butyl (2S,4S)-2-(5-iodo-1H-benzimidazol-2-yl)-4-methyl-pyrrolidine-1-carboxylate 在 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 potassium phosphate 、 四(三苯基膦)钯 、 potassium acetate 作用下， 以 甲醇 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 生成 tert-butyl (2S,4S)-4-methyl-2-[5-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]-1H-benzimidazol-2-yl]pyrrolidine-1-carboxylate
  参考文献：
  名称：

  Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores

  摘要：

  Inhibitors of the HCV NS5A nonstructural protein are showing promising clinical potential in the treatment of hepatitis C when used in combination with other direct-acting antiviral agents. Current NS5A clinical candidates such as daclatasvir, ledipasvir, and ombitasvir share a common pharmacophore that features a pair of (S)-methoxycarbonylvaline capped pyrrolidines linked to various cores by amides, imidazoles and/or benzimidazoles. In this Letter, we describe the evaluation of NS5A inhibitors which contain alternative heteroaromatic replacements for these amide mimetics. The SAR knowledge gleaned in the optimization of scaffolds containing benzoxazoles was parlayed toward the identification of potent NS5A inhibitors containing other heteroaromatic replacements such as indoles and imidazopyridines. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.12.042

文献信息

• Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors
  作者：Simon Giroux、Jinwang Xu、T. Jagadeeswar Reddy、Mark Morris、Kevin M. Cottrell、Caroline Cadilhac、James A. Henderson、Oliver Nicolas、Darius Bilimoria、Francois Denis、Nagraj Mani、Nigel Ewing、Rebecca Shawgo、Lucille L’Heureux、Subajini Selliah、Laval Chan、Nathalie Chauret、Francoise Berlioz-Seux、Mark N. Namchuk、Anne-Laure Grillot、Youssef L. Bennani、Sanjoy K. Das、John P. Maxwell

  DOI：10.1021/ml300461f

  日期：2014.3.13

  The discovery of potent thienoimidazole-based HCV NS5A inhibitors is herein reported. A novel method to access the thienoimidazole [5,5]-bicyclic system is disclosed. This method gave access to a common key intermediate (6) that was engaged in Suzuki or Sonogashira reactions with coupling partners bearing different linkers. A detailed study of the structure-activity relationship (SAR) of the linkers

  本文报道了基于噻吩并咪唑的有效HCV NS5A抑制剂的发现。公开了一种访问噻吩并咪唑[5,5]-双环系统的新方法。该方法可以访问共同的关键中间体（6），该中间体与带有不同接头的偶联配偶体一起参与Suzuki或Sonogashira反应。对接头的结构-活性关系（SAR）的详细研究表明，对于1a和1b HCV基因型而言，具有线性拓扑结构的芳族接头必须具有很高的效价。具有对苯基接头的化合物20被鉴定为潜在的铅，分别针对基因型1a和1b复制子显示17和8 pM的效力。
• [EN] ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS<br/>[FR] ANALOGUES DESTINÉS AU TRAITEMENT OU À LA PRÉVENTION D'INFECTIONS À FLAVIVIRUS
  申请人：VERTEX PHARMA

  公开号：WO2011119858A1

  公开（公告）日：2011-09-29

  Compounds represented by Formula (I) or pharmaceutically acceptable salts thereof, wherein A, B, B', X, Y, R1; R2, R2', R3, R3', R4, R5, R5'm, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

  公式（I）所代表的化合物或其药学上可接受的盐，其中A，B，B'，X，Y，R1；R2，R2'，R3，R3'，R4，R5，R5'm，n或p的定义如本文所述，可用于治疗黄病毒科病毒感染。
• ANALOGUES FOR THE TREATMENT OR PREVENTION OF FLAVIVIRUS INFECTIONS
  申请人：Pereira Oswy Z.

  公开号：US20130085150A1

  公开（公告）日：2013-04-04

  Compounds represented by formula I or pharmaceutically acceptable salts thereof, wherein A, B, B′, X, Y, R 1 , R 2 , R 2 ′, R 3 , R 3 ′, R 4 , R 4 ′, R 5 , R 5 ′m, n, or p are as defined herein, are useful for treating flaviviridae viral infections.

  公式I代表的化合物或其药学上可接受的盐，其中A、B、B′、X、Y、R1、R2、R2′、R3、R3′、R4、R4′、R5、R5′、m、n或p的定义如本文所述，对于治疗黄病毒科病毒感染是有用的。